Project CBD, one of our most trusted sources, investigates a pre-clinical animal study you may have heard about, and which may have left you concerned.
Project CBD, however, finds that the work and the press reporting on it is full of speculation, assumptions and hype, and they put the data, the problems in the study, and its interpretation into context.
"The breathless reporting in Forbes focuses on a single, flawed, pre-clinical study and exaggerates it to the point of falsehood. Yet if there’s a saving grace of the Forbes article, it’s that it gets much less wrong than the study itself. The study is freely available from Molecules, a journal published by the Multidisciplinary Digital Publishing Institute (MDPI).
A close examination of the Molecules study reveals a Pandora’s box of strange statements, problematic publishing and unreasonable experimental design."
Do read on for a useful primer on how not to do cannabis science.
And no, there is still no evidence that natural CBD in the kinds of doses humans take poses any danger to human livers.
That leaves the question about hepatic cautions raised in the FDA clinical trials of Epidiolex, a new-ish prescription drug derived (in some proprietary fashion) from actual CBD, but we know of no study which has found such effects in humans taking typical doses of either full-spectrum or hemp-derived CBD. Again we're not saying they're impossible, just that they're not documented, and certainly not by the study in the article.
Finally, FTR, we still know of no real therapeutic advantages that this expensive drug has over much less costly actual natural CBD. Other than that physicians can prescribe it all 50 states because it's classified as Schedule II.
To our knowledge the RX drug and medicinal plant preparations haven't been directly compared in any actual studies, and we wouldn't be surprised if the maker wasn't anxious to sponsor any such studies which might not show it had an advantage commensurate with its price.
PS: In a competitive publishing world where clicks mean everything to most publishers, we've noticed that Forbes' reporting on various topics is quite sensationalized for a publication that strives for a mainstream reputation we have doubts it deserves. Our two cents, FWIW, but we do our best to watch out for your interests.
The huge popularity of cannabidiol has helped to destigmatize the plant and restore its reputation as an important medicinal herb. But bogus science and inept reporting continue to distort how we understand the benefits and risks of CBD and cannabis.